23804-68-4

Basic information

• Product Name: 4-(aminomethyl)-1-benzylpiperidin-4-ol
• Synonyms: 4-(aminomethyl)-1-benzylpiperidin-4-ol;4-(aMinoMethyl)-1-benzylpiperidin-4-ol dihydrochloride
• CAS NO: 23804-68-4
• Molecular Formula: C₁₃H₂₀N₂O
• Molecular Weight: 220.3107
• Mol File: 23804-68-4.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 366.4±22.0 °C(Predicted)
• Appearance: /
• Density: 1.124±0.06 g/cm3(Predicted)
• PKA: 12.55±0.20(Predicted)
• CAS DataBase Reference: 4-(aminomethyl)-1-benzylpiperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(aminomethyl)-1-benzylpiperidin-4-ol(23804-68-4)
• EPA Substance Registry System: 4-(aminomethyl)-1-benzylpiperidin-4-ol(23804-68-4)

Safety Data

• Hazardous Substances Data: 23804-68-4(Hazardous Substances Data)

Usage

General Description

4-(aminomethyl)-1-benzylpiperidin-4-ol, also known as Nafamostat, is a synthetic and broad-spectrum serine protease inhibitor. This chemical has been used as a medication in Japan for the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and various other conditions. Nafamostat has also shown potential as a treatment for COVID-19, as it has been found to inhibit the replication of the virus in vitro. Additionally, it has been investigated for its potential use in preventing blood coagulation and as an anti-inflammatory agent. Despite its therapeutic potential, further research is needed to fully understand the effects and potential uses of 4-(aminomethyl)-1-benzylpiperidin-4-ol.

Upstream product

• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 7677-24-9 trimethylsilyl cyanide 
• 19867-34-6 N-benzyl-1-oxa-6-azaspiro[2,5]-octane 
• 156215-49-5 1-benzyl-4-(trimethylsilyloxy)piperidine-4-carbonitrile 

Downstream Products

• 5053-14-5 8-Benzyl-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 177948-01-5 [[4-hydroxy-1-(phenylmethyl)-4-piperidinyl]methyl]carbamic acid 1,1-dimethylethyl ester 
• 1607837-16-0 8-(2-amino-3-chloro-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 
• 1607837-47-7 8-(2-amino-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-(trifluoromethyl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 
• 23804-77-5 8-(4-nitro-phenethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 23804-80-0 8-(4-amino-phenethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 5052-95-9 1-oxa-3,8-diazaspiro[4.5]-decan-2-one 
• 23866-35-5 N,N-dimethyl-4-[2-(2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)-ethyl]-benzenesulfonamide 
• 5053-04-3 N-(4-ethoxy-phenyl)-2-(2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)-acetamide 
• 5053-02-1 8-(3-trifluoromethyl-phenethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.